Advertisement
UK markets close in 6 hours
  • FTSE 100

    8,090.66
    +50.28 (+0.63%)
     
  • FTSE 250

    19,721.74
    +2.37 (+0.01%)
     
  • AIM

    755.25
    +0.56 (+0.07%)
     
  • GBP/EUR

    1.1672
    +0.0028 (+0.24%)
     
  • GBP/USD

    1.2515
    +0.0053 (+0.42%)
     
  • Bitcoin GBP

    51,174.63
    -1,922.00 (-3.62%)
     
  • CMC Crypto 200

    1,364.87
    -17.70 (-1.28%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.85
    +0.04 (+0.05%)
     
  • GOLD FUTURES

    2,338.50
    +0.10 (+0.00%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,992.81
    -95.89 (-0.53%)
     
  • CAC 40

    8,054.17
    -37.69 (-0.47%)
     

Rise in healthcare stocks lifts European equities

LONDON, Jan 12 (Reuters) - A rise in healthcare shares, following renewed signs of industry consolidation after Shire Plc agreed to buy NPS Pharmaceuticals (NasdaqGS: NPSP - news) for $5.2 billion, lifted European equities on Monday.

The pan-European FTSEurofirst 300 index rose 0.3 percent to 1,352.67 points in early session trading, while the euro zone's blue-chip Euro STOXX 50 index advanced 0.6 percent.

Britain's FTSE 100 climbed 0.3 percent, helped by a 1.4 percent rise in Shire (Xetra: S7E.DE - news) after its deal to buy NPS.

"The Shire deal is likely to mean that there will be no fresh bid speculation coming through on Shire itself, although the ongoing consolidation within the industry means the sector will remain of interest to investors," said Terry Torrison, managing director at Monaco-based McLaren Securities.

ADVERTISEMENT

Other healthcare stocks also advanced, with the STOXX Europe 600 Healthcare Index rising 0.8 percent.

Roche rose 1 percent after Roche's move to acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc (NasdaqGS: FMI - news) for up to $1.18 billion.

Sanofi (NasdaqGM: GCVRZ - news) also climbed 1.5 percent after the European Medicines Agency agreed to review an application by Sanofi and Regeneron for their cholesterol-lowering drug alirocumab. (Reporting by Sudip Kar-Gupta; Editing by Atul Prakash)